Glaucoma 360, 2017
    Diagnostic & Imaging, Glaucoma

    In this interview from Glaucoma 360, 2017, Dr. Jeffrey L. Goldberg discusses the importance of finding new clinical biomarkers to detect glaucoma, monitor progression and assess response to therapies. His studies are a part of an ongoing collaborative project funded by the Glaucoma Research Foundation’s Catalyst for a Cure initiative. The team’s recent findings include a retinal ganglion cell (RGC) subtype that responds early to glaucomatous damage and evidence of mitochondrial fragmentation in the axons of affected RGCs. The group is also developing a new visual field test and imaging techniques so that these laboratory findings may be applied to clinical practice.